Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aytu BioPharma, Inc. - Common Stock (NQ:AYTU)

2.280 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aytu BioPharma, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
Via ACCESSWIRE
News headline image
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
Via ACCESSWIRE
News headline image
Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and... 
Via Newsfile
News headline image
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Via ACCESSWIRE
News headline image
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
Via ACCESSWIRE
News headline image
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
Via ACCESSWIRE
News headline image
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
Via ACCESSWIRE
News headline image
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
Via ACCESSWIRE
News headline image
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year
Via ACCESSWIRE
News headline image
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
Via ACCESSWIRE
News headline image
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
Via ACCESSWIRE
News headline image
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
Via ACCESSWIRE
News headline image
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023
Via ACCESSWIRE
News headline image
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
Via ACCESSWIRE
Aytu BioPharma Inc. (NASDAQ: AYTU) Near the Top of Equities by Percentage Gain on 9/28
Via Investor Brand Network
News headline image
Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023
Via ACCESSWIRE
News headline image
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market
Via ACCESSWIRE
News headline image
Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer
Via ACCESSWIRE
News headline image
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023
Via ACCESSWIRE
News headline image
Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023
Via ACCESSWIRE
News headline image
Aytu BioPharma to Present at LD Micro Main Event XVI Conference
Via ACCESSWIRE
News headline image
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the... 
Via Newsfile
News headline image
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority
Via ACCESSWIRE
News headline image
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023
Via ACCESSWIRE
News headline image
Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
Via ACCESSWIRE
News headline image
Aytu to Participate in the Maxim Group Virtual Healthcare Conference
Via ACCESSWIRE
News headline image
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director
Via ACCESSWIRE
News headline image
Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results
Via ACCESSWIRE
News headline image
Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023
Via ACCESSWIRE
News headline image
Aytu BioPharma Subleases a Portion of Its Manufacturing Facility
Via ACCESSWIRE
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.